Overview Request Sample Pages Request Customization Download PDF
You are viewing: India Preimplantation Genetic Testing Market analysis

The India Preimplantation Genetic Testing Market was valued at $14.3 Million in 2025 and projected to reach to $25.6 Million by 2030, representing a compound annual growth rate of 12.5%. India's preimplantation genetic testing market is poised for sustained growth through 2030, driven by increasing prevalence of genetic disorders, rising disposable incomes, and growing acceptance of IVF with genetic screening among Indian couples.

India Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Preimplantation Genetic Testing Market Trends and Insights

  • This 12.5% compound annual growth rate reflects India's rising adoption of advanced reproductive technologies and increasing awareness among fertility clinics and patients.
  • India's growing middle class, coupled with improving healthcare infrastructure and declining costs of genetic testing, is driving demand for PGT services across major metropolitan centers and emerging fertility hubs. The Indian PGT market benefits from a large patient base seeking assisted reproductive treatments and a regulatory environment increasingly supportive of genetic screening technologies.
  • India's position as a global fertility destination further accelerates market penetration, as international patients seek cost-effective PGT solutions.
  • Between 2025 and 2030, India is expected to witness significant investments in diagnostic laboratories and fertility clinics equipped with advanced PGT capabilities, positioning the country as a key growth engine within the Asia Pacific region..

Key Market Statistics

  • CAGR (2025-2030) 12.5% CAGR
  • Market Size, 2025 ~USD 14.3 Million
  • Forecast, 2030 ~USD 25.6 Million
  • Country India

India Preimplantation Genetic Testing Market Overview

Rapid Market Expansion :

India's PGT market is growing at 12.5% CAGR, significantly outpacing the global rate of 10.5%, driven by increasing fertility clinic adoption and patient awareness across metropolitan and tier-2 cities.

Rising Middle-Class Demand :

India's expanding middle class and improving healthcare infrastructure are fueling demand for advanced reproductive technologies, with couples increasingly seeking genetic screening for hereditary conditions and chromosomal abnormalities.

Fertility Clinic Growth :

The proliferation of assisted reproductive technology (ART) centers across India, particularly in Delhi, Mumbai, Bangalore, and Hyderabad, is accelerating PGT adoption and service accessibility in the country.

Regulatory Support & Affordability :

Improved regulatory frameworks and competitive pricing compared to Western markets are making PGT services more accessible to Indian patients, positioning India as a medical tourism hub for genetic testing.

India Preimplantation Genetic Testing Market Dynamics

  • The market's 12.5% CAGR reflects strong demand from fertility clinics seeking to offer comprehensive reproductive solutions and from patients prioritizing healthy pregnancies. Key growth catalysts include expanding healthcare infrastructure in tier-2 and tier-3 cities, rising medical tourism, and enhanced awareness campaigns by fertility organizations.
  • However, market penetration remains concentrated in urban centers, presenting significant untapped opportunities in semi-urban regions as technology becomes more affordable and accessible..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • India's PGT market is valued at USD 14.3 million in 2025 and is forecast to grow to USD 25.6 million by 2030, representing a 12.5% CAGR.
      • India's large population, rising infertility rates, and growing middle class are primary drivers of PGT adoption across the country.
      • India's status as a global fertility tourism destination enhances market growth as international patients seek affordable, high-quality PGT services.
      • Declining genetic testing costs and expanding laboratory infrastructure in India are expected to accelerate market penetration through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      India Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES3.63.94.44.95.56.27812.9
      FERTILITY CLINICS10.311.212.413.815.417.319.52212.2
      HOSPITALS2.62.833.33.74.14.65.211.2
      OTHER END USERS11.11.21.31.51.61.8210.5
      TOTAL17.4192123.326.129.232.937.112.1

      Target Audience

      • Fertility Clinic Operators : Clinic owners and medical directors need India market data to assess PGT service demand, benchmark adoption rates, and develop competitive service portfolios aligned with patient expectations.
      • Diagnostic & Lab Companies : Genetic testing laboratories and diagnostic equipment manufacturers require India-specific market insights to identify clinic partnerships, pricing strategies, and technology adoption opportunities.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive health ventures in India need validated market size, growth projections, and competitive dynamics to assess portfolio opportunities and ROI potential.
      • Medical Device & Biotech Firms : Companies developing PGT technologies and reagents need India market intelligence to guide product localization, distribution partnerships, and go-to-market strategies in this high-growth region.
      • Healthcare Consultants & Advisors : Strategy consultants and business advisors serving healthcare clients require India-specific PGT data to support market entry strategies, competitive positioning, and growth recommendations.

      Key Companies in the India Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation (USD 14.3M in 2025) and verified 12.5% CAGR projections for India, enabling accurate business planning and investment decisions in the high-growth reproductive genetics sector.
      • Competitive Landscape Intelligence : Understand India-specific fertility clinic dynamics, key market players, service adoption rates, and regional variations across major metros to identify partnership and expansion opportunities.
      • Patient Demand & Segmentation : Access detailed insights into Indian patient demographics, awareness levels, willingness-to-pay, and geographic demand patterns to tailor marketing strategies and service offerings effectively.
      • Regulatory & Reimbursement Insights : Gain clarity on India's evolving regulatory framework, insurance coverage trends, and government policies affecting PGT adoption to navigate compliance and pricing strategies.
      • Strategic Growth Roadmap : Leverage India-specific forecasts through 2030 to identify high-potential segments, tier-2/tier-3 city expansion opportunities, and medical tourism positioning for sustainable market penetration.

      Frequently asked questions

      What is the current market size of PGT in India?

      India's preimplantation genetic testing market was valued at USD 14.3 million in 2025 and is expected to grow significantly through the forecast period.

      What is the projected growth rate for India's PGT market?

      India's PGT market is projected to grow at a compound annual growth rate (CAGR) of 12.5% from 2025 to 2030.

      What will India's PGT market size be by 2030?

      India's preimplantation genetic testing market is forecast to reach USD 25.6 million by 2030, nearly doubling from 2025 levels.

      What factors are driving PGT market growth in India?

      Key drivers include India's large population, rising infertility awareness, growing middle class purchasing power, declining test costs, and India's position as a global fertility destination.

      How does India's PGT market compare to global trends?

      India's 12.5% CAGR exceeds the global average of 10.5%, positioning India as a faster-growing market within the Asia Pacific region and globally.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status